Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 802 across all filing types
Latest filing 2008-04-23 Regulatory Filings
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
PHARMING STARTS CLINICAL PROGRAM IN AGEING DISEASES
Regulatory Filings Classification · 93% confidence The document is a press release dated April 23, 2008, announcing that Pharming Group NV's subsidiary has started a Phase I clinical study for its product Prodarsan®. It details the purpose of the study (pharmacokinetics and tolerability), the target disease (premature ageing/Cockayne Syndrome), and the next steps. This content aligns perfectly with an Earnings Release (ER) or a general announcement regarding clinical trial progress, which often accompanies or precedes formal financial reporting. Since it is a specific announcement about a clinical trial milestone rather than a comprehensive financial report (10-K, IR) or a general management discussion (MDA), and it is not a transcript (CT) or a formal regulatory filing notification (RPA/RNS), the most fitting category for a specific operational/pipeline update announced via press release is the Earnings Release (ER) category, as these announcements often serve as the primary communication channel for non-financial operational news between reporting periods, or the Regulatory Filing (RNS) as a general announcement. Given the nature of the announcement (clinical trial start), it is a significant operational update. However, since it is not explicitly an earnings announcement, and it is a detailed operational update, it fits best under the general Regulatory Filings (RNS) category if a more specific operational code isn't available, or potentially an Investor Presentation (IP) if it were structured as slides, but it reads like a standard press release. Comparing the options, it is a specific operational update announced via a press release. It is not a full report, nor a management discussion. Given the available codes, RNS (Regulatory Filings - general/miscellaneous) is the safest fallback for a press release detailing clinical progress that isn't explicitly an ER or IR. However, if we interpret 'ER' broadly as 'key operational/pipeline news release', it could fit there. Given the strong focus on clinical trial progress, and lack of explicit financial results, RNS is the most appropriate general classification for a non-standard announcement.
2008-04-23 English
Pharming announces first quarter 2008 results
Interim / Quarterly Report Classification · 100% confidence The document is a quarterly financial results announcement for Pharming Group NV for the period ended March 31, 2008. It contains a narrative summary of financial performance, operational developments, and includes the full consolidated balance sheet, income statement, and cash flow statement. Since it provides comprehensive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report (IR). Q1 2008
2008-04-18 English
Pharming provides update on business strategy at shareholders meeting
Board/Management Information Classification · 99% confidence The document explicitly states that Pharming Group NV 'will provide an update of its business strategy during the Annual Meeting of Shareholders later today.' It also discusses organizational changes in the Board of Management and Supervisory Directors, and details the company's focus on Rhucin® development. The presence of 'Shareholders Meeting' and the context of providing strategic updates strongly suggests this material is related to the Annual General Meeting (AGM). Since it is an update provided *at* the meeting, AGM-R (AGM Information) is the most appropriate classification, rather than a proxy statement (PSI) or a general earnings release (ER).
2008-04-16 English
Pharming's Annual General Meeting of Shareholders to be held in Leiden on 16 April 2008
AGM Information Classification · 98% confidence The document text is in Dutch and explicitly announces the date, time, and location for the 'Jaarlijkse Algemene Vergadering van Aandeelhouders' (Annual General Meeting of Shareholders, or AGM). It states that the official notice will be published on April 1, 2008, and relevant documents will be available then. Since this document is an announcement *about* the AGM, rather than the presentation materials themselves or the voting results, it fits best under AGM Information (AGM-R). The document length is short (2039 chars), but the content is a direct announcement of the meeting, not just a notice that materials are attached, making AGM-R more specific than RPA or RNS.
2008-03-04 English
Pharming's Annual General Meeting of Shareholders to be held in Leiden on 16 April 2008
AGM Information Classification · 98% confidence The document explicitly announces the date, time, and location for the 'Annual General Meeting of Shareholders (AGM)'. It mentions that related documentation will be made available on a specific date. This content directly relates to the scheduling and announcement of the AGM, fitting the definition for AGM Information (AGM-R). Although it is an announcement, the core subject is the meeting itself, which is more specific than a general Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2008-03-04 English
Pharming concludes license agreement with Advanced Cell Technology
Capital/Financing Update Classification · 95% confidence The document is a press release dated February 28, 2008, announcing that Pharming Group NV has entered into a license agreement with Advanced Cell Technology Inc. to acquire exclusive rights to patents related to transgene technology. This announcement concerns a significant business development, specifically related to intellectual property and technology control, which falls under corporate transactions or strategic updates. Since there is no specific category for 'Technology Licensing Agreement' and it is not a standard financial report (10-K, IR, ER), nor a management change (MANG) or dividend (DIV), it best fits the general category for significant corporate announcements that are not explicitly covered elsewhere. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general, non-standard corporate announcement, although 'Capital/Financing Update' (CAP) could sometimes cover IP deals if they involve significant capital structuring, but here it is purely about IP rights acquisition. Given the nature of the announcement (a strategic business deal announcement), RNS is the safest general classification when a more specific one is missing.
2008-02-29 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.